Related Experiment Video
Updated: Feb 10, 2026
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
Potential Anti-Inflammatory Treatment of Ischemic Heart Disease
1Clinic for Heart, Blood Vessel and Rheumatic Diseases. University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.
Insights
This study found that additional treatment for ischemic heart disease (IHD) patients, including specific vitamins and ampicillin, moderately improved systolic function and significantly reduced major adverse cardiac events (MACE) by targeting inflammation and atherosclerosis.
Area of Science:
- Cardiology
- Inflammation Research
- Atherosclerosis Studies
Background:
- Ischemic heart disease (IHD) is a major global cause of mortality, driven by atherosclerosis and chronic inflammation in coronary arteries.
- Current therapeutic strategies for IHD often focus on managing symptoms, with less emphasis on directly addressing the underlying inflammatory processes within atherosclerotic lesions.
Purpose of the Study:
- To investigate the efficacy of an add-on therapy targeting inflammation and atherogenesis in patients with ischemic heart disease.
- To evaluate the impact of this combined treatment on major adverse cardiac events (MACE) and cardiac systolic function.
Main Methods:
- A prospective, comparative study involving 80 IHD patients with controlled biohumoral, atherogenic, and inflammatory markers.
- The experimental group (38 patients) received conventional IHD treatment plus ampicillin, cyanocobalamin, vitamin B complex, and folacin.
- The control group (42 patients) received only conventional IHD treatment.
Main Results:
- A strong positive correlation was observed between MACE and inflammatory markers (CRP, amyloid) and the atherogenic marker homocysteine.
- The experimental group showed a moderate improvement in left ventricular systolic function compared to the control group.
- The add-on therapy significantly reduced MACE, including postinfarct angina, reinfarction, and cardiac insufficiency, over a one-year follow-up.
Conclusions:
- The applied add-on treatment demonstrated a significant reduction in MACE and a moderate positive effect on systolic function in IHD patients.
- The findings suggest a potential anti-inflammatory effect of the combined therapeutic approach.
- Targeting inflammatory processes in conjunction with conventional treatment may improve outcomes for IHD patients.
Introduction:
Ischemic heart disease (IHD) is clinical manifestation of chronic inflammatory progressive pathological process of atherosclerosis in coronary arteries. IHD is the leading cause of morbidity and mortality in the world. The question is whether it is possible to improve and direct the therapeutic treatment of IHD patients in the treatment of the inflammatory process in the atherosclerotic leasions.
Material And Methods:
A prospective, comparative, analytica,clinically applicable, open-type study was performed. The study was conducted on 80 subjects with controlled biohumoral markers: troponin, CK, CK MB, BNP; markers of atherogenesis: LDL and homocystein; inflammatory markers: CRP, amyloid, cytokines IL-2, IL-6,TNF-alpha. The experimental group of 38 respondents had in addition to the conventional IHD treatment with: ampicillin (which included organosulfur compounds), cyancobalamin, vitamin B complex (B1, B2 and B6) and folacin. A control group of 42 respondents did not have this additional treatment.
Results:
Major adverse cardic events (MACE) such as postinfarctic angina pectoris and repeated infarction, need for surgical interventions of myocardial revascularization, signs of cardiac insufficiency and death were observed during the one-year period. There was no correlation between the IL-2, IL-6 and TNF-alpha, as well as CK, CKMB and troponin and MACE in one-year follow-up. There was a strong positive correlation between MACE and CRP (p = 0,0002) and amyloid (p = 0,0005) as inflamatory markers; a strong positive correlation between MACE and homocysteine as an atherogenic marker (p = 0,0002, and amoderate positive correlation between MACE and BNP (p = 0.0403) as ischemic marker and marker of cardiac insufficiency. The echocardiographically monitored systolic function showed a moderate difference in the groups with average higher values in the experimantal group (p = 0.0282).
Conclusion:
The applied treatment exhibited a moderate positive effect on the systolic function of LV and significantly reduced the MACE in the work compared to the control group (p <0.0001), and demonstrated a potential anti-inflammatory effect.
More Related Videos
05:06Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
Published on: May 5, 2020
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...